---
title: "Ascentage Pharma to Showcase Six Cancer Drug Studies at 2026 ASCO Meeting"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/283571877.md"
description: "Ascentage Pharma Group International (HK:6855) will present data from six clinical studies at the 2026 ASCO Annual Meeting in Chicago, focusing on three key drug candidates. The presentations include rapid oral and poster formats, showcasing targeted therapies for adult hematologic cancers and pediatric solid tumors. Notable studies feature Olverembatinib for advanced leukemia and Alrizomadlin for pediatric patients with soft-tissue sarcomas. Analysts rate the stock as a Buy with a target price of HK$93.00, reflecting confidence in the company's innovative oncology therapies."
datetime: "2026-04-21T23:07:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/283571877.md)
  - [en](https://longbridge.com/en/news/283571877.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/283571877.md)
---

# Ascentage Pharma to Showcase Six Cancer Drug Studies at 2026 ASCO Meeting

### Claim 30% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

The latest announcement is out from Ascentage Pharma Group International ( (HK:6855) ).

Ascentage Pharma will present data from six clinical studies involving three key drug candidates at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago, underscoring the company’s growing presence in cutting-edge cancer research. Three of the selected abstracts are rapid oral presentations and three are poster presentations, highlighting the clinical potential of its targeted therapies in both adult hematologic cancers and pediatric solid tumors.

Two of the rapid oral presentations will feature Olverembatinib, including its use in combination with blinatumomab for advanced leukemia and updated efficacy and safety data as a second-line therapy in chronic-phase chronic myeloid leukemia. A third rapid oral presentation will cover Alrizomadlin alone or with Lisaftoclax in pediatric patients with relapsed or metastatic rhabdomyosarcoma and other soft-tissue sarcomas, potentially strengthening Ascentage Pharma’s positioning in both hematology and pediatric oncology segments.

The most recent analyst rating on (HK:6855) stock is a Buy with a HK$93.00 price target. To see the full list of analyst forecasts on Ascentage Pharma Group International stock, see the HK:6855 Stock Forecast page.

**More about Ascentage Pharma Group International**

Ascentage Pharma Group International is a Hong Kong–listed biopharmaceutical company focused on developing innovative oncology therapies. Its leading products include Olverembatinib, the first third-generation BCR-ABL inhibitor approved in China, Lisaftoclax, a China-developed Bcl-2 selective inhibitor, and Alrizomadlin, an MDM2-p53 inhibitor, targeting hematologic malignancies and solid tumors in global markets.

**Average Trading Volume:** 2,073,352

**Technical Sentiment Signal:** Buy

**Current Market Cap:** HK$19.67B

For a thorough assessment of 6855 stock, go to TipRanks’ Stock Analysis page.

### Related Stocks

- [06855.HK](https://longbridge.com/en/quote/06855.HK.md)
- [AAPGV.US](https://longbridge.com/en/quote/AAPGV.US.md)
- [AAPG.US](https://longbridge.com/en/quote/AAPG.US.md)

## Related News & Research

- [Ascentage Pharma Showcases Four Preclinical Cancer Programs at 2026 AACR Meeting](https://longbridge.com/en/news/279513407.md)
- [BeOne Medicines Shares Surge After Robust First-Quarter](https://longbridge.com/en/news/285495342.md)
- [ZAWYA: Almarai signs an agreement to support children with Rheumatism](https://longbridge.com/en/news/285394877.md)
- [What is your AI drug repurposing strategy missing?](https://longbridge.com/en/news/285099080.md)
- [BUZZ-Replimune falls after FDA's Makary defends decision on cancer drug](https://longbridge.com/en/news/285229479.md)